scispace - formally typeset
R

Richard N. Bergman

Researcher at Cedars-Sinai Medical Center

Publications -  489
Citations -  97005

Richard N. Bergman is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Insulin & Insulin resistance. The author has an hindex of 130, co-authored 477 publications receiving 91718 citations. Previous affiliations of Richard N. Bergman include University of Southern California & University of California, Los Angeles.

Papers
More filters

123-LB: Extended Fasting Reveals Effect of Canagliflozin to Mobilize Ketones in Canines

TL;DR: Effect of SGLT2i on ketones is manifest after 24 h of total food restriction, after which reduction in carbohydrate stores switches animals to fat-based metabolism, characterized by increased FFA and ketosis.
Journal ArticleDOI

Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin‐resistant canine model

TL;DR: In this paper , the effects of the SGLT2i dapagliflozin (DAPA) on subcutaneous (SC) and visceral (VIS) adipose tissue function remain unclear.
Journal ArticleDOI

1342-P: Reduction of Glucokinase and Glucokinase Regulatory Protein Expression by siRNA Is Associated with the Reduction of Lactate and Pyruvate Export from Canine Hepatocytes

TL;DR: It is shown that direct suppression of GCK and GKRP genes by siRNA in vitro affects glucose-responsive glycolysis genes, consequently reducing lactate export which can be used as a surrogate for reduced glucokinase activity in hepatocytes.
Journal ArticleDOI

365-OR: A Machine-Learning Approach to Estimate Insulin Resistance from Untargeted Metabolomics Data

TL;DR: In this paper , the authors developed estimation models for the dynamic measure of insulin sensitivity (SI) and the basal measure of homeostatic model assessment of IR (HOMAIR) from metabolomics data combined with minimal clinical data, e.g. age, sex, BMI.